Experts with the University of Vermont Health Network taking medical and scientific questions Tuesday about the Johnson & Johnson vaccine, following the statewide pause on distribution. These clots associated with the vaccine have been identified in 6 people, mainly women under the age of 50 years old. Experts say that there is no indication yet as to why this demographic has been most effected. The specific clotting reported is unusual, only seen in about 1 in 100,000 of their patients each year. “It appears to be an abnormal immune reaction which I would conclude is possibly or likely due to the vaccine,” Dr. Mary Cushman from UVM Health Network. “It is not something that is like a known disease that we see on a frequent basis.”The Johnson & Johnson vaccine is designed similarly to the AstraZenca vaccine. The doctors say the clotting concerns with the AstraZenca vaccine seem similar to what is being reported with Johnson & Johnson. Those who received the AstraZenca vaccine as a part of UVM’s trial, however, have not dealt with any clotting issues.
Experts with the University of Vermont Health Network taking medical and scientific questions Tuesday about the Johnson & Johnson vaccine, following the statewide pause on distribution.
These clots associated with the vaccine have been identified in 6 people, mainly women under the age of 50 years old. Experts say that there is no indication yet as to why this demographic has been most effected. The specific clotting reported is unusual, only seen in about 1 in 100,000 of their patients each year.
Advertisement
“It appears to be an abnormal immune reaction which I would conclude is possibly or likely due to the vaccine,” Dr. Mary Cushman from UVM Health Network. “It is not something that is like a known disease that we see on a frequent basis.”
The Johnson & Johnson vaccine is designed similarly to the AstraZenca vaccine. The doctors say the clotting concerns with the AstraZenca vaccine seem similar to what is being reported with Johnson & Johnson. Those who received the AstraZenca vaccine as a part of UVM’s trial, however, have not dealt with any clotting issues.